Effects of glepaglutide, a novel long-acting glucagon-like peptide-2 analogue, on markers of liver status in patients with short bowel syndrome: findings from a randomised phase 2 trial

Authors: Rahim Mohammad Naimi, Mark Hvistendahl, Nikolaj Nerup, Rikard Ambrus, Michael Patrick Achiam, Lars Bo Svendsen, Henning Grønbæk, Holger Jon Møller, Hendrik Vilstrup, Adam Steensberg, Palle Bekker Jeppesen

Published: 2019-07-17

DOI: 10.1016/j.ebiom.2019.07.016

Source: Full article

---

Abstract

No abstract found.